A sound theoretical rationale for the design of a magnetic nanocarrier capable of magnetic capture in vivo after intravenous administration could help elucidate the parameters necessary for in vivo magnetic tumor targeting. In this work, we utilized our long-circulating polymeric magnetic nanocarriers, encapsulating increasing amounts of superparamagnetic iron oxide nanoparticles (SPIONs) in a biocompatible oil carrier, to study the effects of SPION loading and of applied magnetic field strength on magnetic tumor targeting in CT26 tumor-bearing mice. Under controlled conditions, the in vivo magnetic targeting was quantified and found to be directly proportional to SPION loading and magnetic field strength. Highest SPION loading, however, resulted in a reduced blood circulation time and a plateauing of the magnetic targeting. Mathematical modeling was undertaken to compute the in vivo magnetic, viscoelastic, convective, and diffusive forces acting on the nanocapsules (NCs) in accordance with the Nacev−Shapiro construct, and this was then used to extrapolate to the expected behavior in humans. The model predicted that in the latter case, the NCs and magnetic forces applied here would have been sufficient to achieve successful targeting in humans. Lastly, an in vivo murine tumor growth delay study was performed using docetaxel (DTX)-encapsulated NCs. Magnetic targeting was found to offer enhanced therapeutic efficacy and improve mice survival compared to passive targeting at drug doses of ca. 5−8 mg of DTX/kg. This is, to our knowledge, the first study that truly bridges the gap between preclinical experiments and clinical translation in the field of magnetic drug targeting.
S uperparamagnetic iron oxide nanoparticles (SPIONs) have been widely explored for pharmaceutical applications. 1, 2 Their superparamagnetic state ensures no remanent (permanent) moment in the absence of an applied field and obviates the risk of uncontrolled aggregation of the nanoparticles in the bloodstream or tissues. 3 The directed transport of SPIONs in the bloodstream is dependent on a dynamic equilibrium between the magnetic and hydrodynamic forces acting on the SPIONs. 4−8 As a result, the physical properties, including the field strength and gradients, the volumetric and magnetic properties (magnetization) of the particles, and the hydrodynamic parameters such as blood flow, hematocrit, viscosity, and SPION concentration in the blood, are all of importance. 1, 6, 9 Only one study investigating the optimal conditions on magnetic targeting has been reported so far. 10 This study demonstrated that higher magnetic field strength offered better magnetic targeting. However, the conclusion was drawn from a custom-made magnetic setup and mainly determined on the basis of intra-arterial administration, which required invasive surgery. 11 This was presumably due to the limited pharmacokinetic properties such as blood circulation half-life, organ biodistribution, and tumor extravasation ability. Thus, studying the key factors that possibly affect magnetic targeting efficacy is crucial.
In this work, we used oil-cored polymeric magnetic nanocapsules (m-NCs) with tunable SPION loadings and prolonged blood circulation time 12 to better understand the factors influencing magnetic targeting after intravenous injections in vivo. The high SPION loading eliminated the need for using highly magnetized nanoparticles. The oil core facilitated high hydrophobic drug loading compared to that of the polymer-coated SPIONs reported in the literature. 13, 14 Our aim was to assess the key factors influencing magnetic targeting efficacy, including SPION loadings in m-NC and the remotely applied magnetic force magnitude. To translate the results from mouse to human, mathematical modeling was undertaken to compute the in vivo magnetic, viscoelastic, convective, and diffusive forces acting on the m-NCs in accordance with the Nacev−Shapiro construct. 15 The predicted magnetic targeting behavior in mouse vasculature was compared with the observed murine data and then extrapolated to the expected behavior in humans. Docetaxel (DTX) was used as a model hydrophobic anticancer drug to test the therapeutic efficacy of m-NCs in the presence or absence of magnetic targeting.
The use of SPIONs in the biomedical field is advantageous given the superparamagnetic state. Their small size (<30 nm) also allows them to extravasate through the leaky blood vasculature of tumors. 16, 17 However, through the 2000s and 2010s, SPION-based magnetic drug targeting has been the subject of intense debate, with concerns focusing on the minimal magnetic forces generated from the small magnetic cores and the limited blood circulation times of the SPIONs used. 10, 11, 18, 19 To address these issues, we developed a polymeric oil-cored m-NC system prepared with increasing amounts of SPION (0% to ca. 7% w/w SPION−NC, namely NC 1−5) with PEGylated poly(lactic-co-glycolic acid) (PLGA− PEG). 12 The hydrodynamic sizes were in the range of 203−218 nm, and no significant changes were observed over the 3 month storage period (Table 1 and Figure S1 ). A schematic morphological illustration of an m-NC is shown in Figure 1a . m-NCs are expected to have a core−shell structure with SPIONs entrapped within the oil core and surrounded by a polymeric shell and PEGylated outer layer. Figure 1b shows the 2D projections of m-NCs imaged by low-dose cryo-transmission electron microscopy (cryo-TEM), from which the image strongly suggests that a high number of SPIONs (electron-dense nanoparticles) are well-confined within the oil core. The superparamagnetic properties were not compromised as confirmed by the superconducting quantum interference device (SQUID) and Mossbauer spectroscopy analysis ( Figure  1c ,d). This design potentially offered an increase in the apparent magnetic forces acting on the nanocapsules as a whole compared to SPIONs, as magnetic force is directly proportional to the cumulative iron oxide nanoparticle volume within the m-NC core. Fundamental work of biodistribution profiles and tumor accumulation was conducted to understand the key factors in achieving efficacious magnetic targeting. NC 1−5 were radiolabeled with indium-111 (Table S1 ), as we reported previously. 12 Magnetic targeting efficacy was assessed by calculating the fold increase in percentage injected dose per gram of tumor tissue (%ID/g of tumor) upon application of magnetic field.
To explore the effect of SPION loading on magnetic targeting efficiency, mice were injected with comparable NC doses (312.5 mg of polymer/kg) with increased loadings of SPIONs from 0 to ca. 7% w/w in m-NCs. This was achieved by preparing m-NCs with different initial SPION loadings (NC 1− 5). The effect of SPION loading on blood circulation, excretion, organ biodistribution, and tumor accumulation was examined using the formulated m-NC-111 In with magnetic field of 0.43 T. Blood circulation profiles are shown in Figure 2a . All m-NCs displayed prolonged blood circulation time with approximately 40% and 20% remaining in the blood after 1 and 4 h, respectively. m-NCs with the highest SPION loading (ca. 7%, NC 5-111 In), however, showed significantly lower blood circulation by 4 h post-injection (p < 0.05). It is unclear why NC with the highest SPION loading circulated shorter than the other formulations, but one may hypothesize that the iron overloading induced NC instability, more notably under the reasonably high shear forces in vivo. The gradual reduction in ζ potential values, as SPION loading increases, is another parameter that one may want to consider; NC 5 exhibited the lowest ζ potential among all formulation.
Negligible radioactivity was found in feces (0−2% ID/ mouse), and nearly 40% ID/mouse was detected in urine over the first 24 h post-injection period ( Figure 2b ) for all m-NCs. Instant thin-layer chromatography (iTLC) confirmed that only 5.3−9.3% of the excreted radioactivity was in the form of 111 In-DTPA−EDTA chelates indicating that PLGA 18KDa -PEG 3.5KDa -DTPA was excreted intact. Organ biodistribution of In was assessed at 24 h post-injection ( Figure 2c ). The highest uptake was observed in spleen followed by liver and kidney tissue. Increasing SPION loadings led to a gradual increase in liver and spleen uptake and became statistically significant at 7% w/w (p < 0.01). Such results explain the reduction in blood circulation time of m-NCs of highest SPION loading.
Uptake in tumors exposed to magnetic field (TU+) or that remained unexposed (TU−) was quantified and is shown in Figure 2d . Significantly higher % ID/g of tumor was observed in TU+ compared to TU− in NC 2−5 but at a different extent (p < 0.05). No significant differences in % ID/g of tumor (TU−) were observed with m-NCs at increasing loadings of SPION, except for NC 5 with the SPION loading (ca. 7%), which showed the lowest but significant uptake. This was expected as a result of reduced blood circulation time and increased liver and spleen uptake. Despite lower % ID/g of tumor obtained for NC 5, its enhancement in tumor uptake upon magnetic targeting was still significant and comparable to that of NC 4 (Figure 2e ). The effect of SPION loading on in vivo magnetic targeting efficacy was also confirmed by singlephoton emission computed tomography−computed tomography (SPECT−CT) imaging ( Figure 2f and Figure S2 ). Interestingly, signals could be seen in tumors exposed to magnet (TU+) at 1 h post-injection, possibly due to magnetic targeting, while signals in TU− only started to be obvious at 4 h post-injection due to the passive EPR effect. Tumor accumulation of m-NCs was enhanced over time in both tumors for all formulations. Higher intensity was seen in TU+ compared to TU− at all imaging time points studied. Because the m-NCs were also a good magnetic resonance (MR) contrast agent, 12 MR imaging was also performed to confirm the tumor uptake of SPIONs with increasing SPION loadings (Figures 2g and S3 ). Similar to SPECT−CT imaging, more hypo-intense signals (darkening) were seen in TU+ than TU− in mice injected with NC 2−5, indicating higher SPION accumulation in tumors when the magnetic field was applied. The intensities from MRI were not compared between m-NCs due to different initial SPION injection doses (indicated in the Supplementary Methods section).
The effect of magnetic field on tumor uptake was studied using three magnets with different magnetic field strength/ gradients (0.43, 0.41, and 0.30 T) and dimensions (8, 7 , and 6 mm in diameter, respectively). Organ biodistribution for NC 1−5 was not altered when different magnetic field strength and gradients were applied to the tumor ( Figures S4 and S5 , respectively). However, at lower magnetic field strength and gradients (0.30 and 0.41 T), no magnetic targeting was obtained in mice injected with NC 2 (the lowest SPION loading) ( Figures S4c and S5c ). This is most probably because the low magnetic field provided insufficient magnetic forces on m-NCs under these conditions. On the contrary, when the strongest magnetic field (0.43 T) was applied, tumor uptake increased linearly when SPION doses increase from 0 to 125 mg SPION/kg. The results suggest that magnetic targeting is still possible at lower magnetic field, but m-NCs of higher SPION loadings are required for this instance. As a result, high SPION loading and magnetic field strength and gradients were therefore proven to be the determining factors to achieve efficient magnetic targeting experimentally. To the best of our knowledge, this is the first study to investigate the influence of the magnetic field, at increasing SPION doses, on magnetic targeting efficacy in vivo.
Another concern in the field of magnetic targeting research is the lack of translation of mouse and rat experimental data to human clinical designs. We, therefore, have applied magnetic force calculation to the in vivo experimental conditions (viz., a 10 mm diameter tumor adjacent to the center of the circular face of the NdFeB actuating magnet) to quantify the magnitude of the magnetic forces experienced by m-NCs as they pass through the tumor (see the Supplementary Methods section and Figures S6−S13). In the case of NC 4 with the 8 mm diameter magnet, these forces range from ca. 0.3 to 6.5 fN per m-NC, with a median force (i.e., the force experienced by an m-NC containing 43 SPIONs per m-NC (the center of the polydispersity range) at the center of the tumor (5 mm from the face of the magnet)) of ca. 1.9 fN per m-NC. This quantification allows us to extrapolate from the observed behavior in the mouse model to the expected behavior in humans by reference to the finite element modeling work of Nacev et al. 20, 21 The Nacev model is particularly useful here because it is formulated in terms of three dimensionless physical parameters (the magnetic Richardson number Ψ, the mass Peclet number Pe, and the reduced Renkin diffusion coefficient D) that may be evaluated for both preclinical and clinical situations. This simulates the competition between the applied magnetic forces, blood convection, and diffusion and therefore reveals the magnetic behaviors of m-NCs under any given physiological conditions. Figure 3a shows the calculated Nacev behavior for the mouse model for the case of NC 4 with the 8 mm diameter magnet (further details on the calculations are given in the Supplementary Methods section) . The magnetic Richardson number Ψ, the mass Peclet number Pe, and the reduced Renkin diffusion coefficient D triad in this case were estimated to be Ψ = 3.0 −2.5 +8.0 × 10 −3 , Pe = 820 ± 360, and D = 0.30 ± 0.13, which places the predicted magnetic targeting behavior firmly in the region of positive capture, i.e., in the "boundary-layer formation" region. 20, 21 The other formulation that positioned in this region was NC 5 (ca. 7% w/w) ( Figure S14 ). m-NCs with lower SPION loadings, such as NC 2 (ca. 0.08% w/w), were mostly located in the velocity-dominated region or the phase-transition layer, indicating that the magnetic forces are weak compared with the blood flow forces; 15 thus, NC 2 are likely to be washed out of the blood vessels, which agreed with our experimental data.
These results made us confident in scaling our mouse experimental results to the virtual human body by fitting the magnetic force calculations into the Nacev model while using human blood hydrodynamic parameters. We adopted the blood and blood vessel parameters in humans from the Lubbe et al. Phase I clinical study, 22 as reported by Nacev et al. 20, 21 and listed in the Supporting Information. Magnetic targeting tends to be more difficult to achieve in humans because human blood velocity and vessel diameters are at least 3 orders of magnitude greater than those observed in both mice and rats. The tissue− membrane diffusion coefficient is also ca. 3-fold higher. Figure  3b shows the predicted Nacev behavior in humans, again for the case of NC 4 and the 8 mm diameter magnet. In this case, the behavior-governing environment parameters were set to values appropriate for ca. 5 mm skin-to-target distance, as defined in an earlier human clinical trial of magnetic targeting of near-to-skin solid tumors. 23 The calculated triad values here were Ψ = 3.0 −2.5 +8.0 × 10 −6 , Pe = 8.3 + 3.6 × 10 5 , and D = 1.0 + 0.4 × 10 −3 . It is apparent from Figure 3b that the predicted magnetic targeting behavior in the human blood vessels remains, for the most part, in the region of positive capture.
When the experimental and mathematical data are taken together, it is obvious that the pharmacokinetic profile of m-NCs also plays a crucial role in determining efficacy of magnetic targeting, apart from the magnetic forces. For example, NC 4 showed higher blood circulation time than NC 5, which agreed with TU+ uptake values (NC 4:5.7%ID/g and NC 5:3.8%ID/g, p < 0.05) and therefore could deliver more drug to a tumor. As a result, the high SPION loading acts as a trade-off between strong magnetic forces and ideal pharmacokinetic properties in a magnetic nanocarrier design. This suggests that for this particular formulation, the optimal SPION loading is ca. 2%, above which the magnetic targeting effect is counterbalanced by shortened blood circulation time due to clearance by the reticular endothelial system (RES); hence, no further improvement in magnetic targeting could be seen.
In this study, the m-NC size of >200 nm was found to perform better in magnetic targeting than the small-sized SPION reported in the literature, more likely due to the enhancement in the magnetic force acting per m-NC as a result of their larger diameter. It is worth noting that this is not the ideal size with which to exploit the EPR effect in mouse tumors and, in particular, also in tumors in human patients. We, however, showed that smaller-sized PLGA-based nanoparticles (size∼ 150 nm), prepared without the oil core, were also able to benefit from magnetic targeting of the tumors (data not shown). It is also worth mentioning that the magnetic field gradient used in this study is relatively low, and stronger magnets can be used if smaller magnetic carriers are to be used. It is crucial to point out that in this study the m-NC were prepared with different amounts of SPION loading, which may influence their size and ζ potential and can indirectly affect the organ biodistribution and magnetic tumor targeting profiles. Despite the gradual reduction in ζ potential as SPION loading increased, our data showed that there was no difference in m-NC size or organ biodistribution profile nor blood circulation time, except for NC 5, which coincidentally exhibited the least negative ζ potential. It is likely that the discrepancy between the modeling results of NC 5 and the in vivo magnetic tumor targeting is related to their dramatically reduced blood circulation time and their reduced ζ potential compared to those of other formulations. One way to overcome this problem could be to prepare m-NC of a fixed SPION loading but then alter the number of m-NCs injected per mouse to alter the SPION dose administered. This approach may have its own limitations, such as different degrees of RES saturation, making this approach not perfect either.
The only in vivo study reported so far is by Chertok et al., 10 which examined the magnetic retention of MNPs under different magnetic field gradients and topography in intracerebral 9L-glioma bearing rats. When magnetic field strength increased from 0.15 to 0.35 T, a 2.1-fold increase in iron content in tumor tissue was observed. The topography of magnetic field also affects the accumulation of MNPs in tumors. The conventional permanent magnets or electromagnets usually generate a relatively uniform magnetic field gradient over a broad range. As a result, all vasculatures, especially tumor arteries, tend to be exposed to high magnetic forces, thereby causing vascular embolism when MNPs are injected intraarterially. 8 In this study, we report that magnetic targeting can be achieved with intravenously injected magnetic nanocarriers. Our study, however, did not offer a solution to targeting deep or metastatic tumors and was only limited to superficial tumors. More innovative solutions are still to be found for magnetically targeting deep tumors.
To test the therapeutic outcome of m-NCs with magnetic targeting, a cancer therapy study was carried out using docetaxel (DTX) as a model hydrophobic drug in a CT26 colon cancer model. DTX suffers from poor water solubility (10−20 μg/L), which hampers its ability to be administered systemically. 24 The only commercial formulation available now is Taxotere DTX (Sanofi-Aventis), but it is reported to have several hypersensitivity reactions and incompatibility with common peripheral venous catheters, 24, 25 so there is ongoing substantial effort to develop better DTX formulations. In this study, DTX was coencapsulated in the SPION-loaded oil-cored polymeric m-NCs with the purpose of effectively delivering high doses of drugs to cancers with the magnetic targeting strategy. 14 The physicochemical properties of DTX loaded m-NCs (m-NC-DTX) were not significantly affected ( Table 2) and m-NC also demonstrated sustained drug-release profiles ( Figure S15a ). An efficient cell-killing effect of m-NC-DTX against the CT26 cell line was observed in the in vitro cytotoxicity study ( Figure S15b ). Therefore, optimal magnetic targeting conditions were employed in the therapy study, i.e., NC 4 (ca. 2%) with the 8 mm diameter magnet. To test the efficacy of magnetic targeting, two different doses of DTX were employed: (i) 5 mg/kg as the low (L) dose (m-NC-DTX L ) and (ii) 8 mg/kg as the high (H) dose (m-NC-DTX H ). Mice were either exposed to the magnet, e.g., DTX + , or remained unexposed, e.g., DTX − . Tumor growth curves responding to different treatments are shown in Figure 4a . Mice injected with DTX H showed signs of significant body weight loss after two or three injections and were sacrificed before the completion of the treatment. Hence, the results are not included. In the other groups, no differences in tumor growth curves were observed between DTX ± L , PBS ± , and m-NC ± (no-drug) treatments, and mice reached the terminal stage on day 19 with tumor volumes of ∼1000 mm 3 . However, tumor growth delay was observed by day 19 in groups receiving m-NC-DTX H with or without magnetic field (337 ± 43 and 645 ± 95 mm 3 To our knowledge, only one study reported the use of DTX against CT26 tumors. This was in a metastasis model using PLGA microparticles at a dose of 8 mg/kg. 26 PLGA microparticles prolonged the median survival times of mice by 10 days. This was similar to the results obtained in this study at the same administration dose when no magnet was applied and at a lower dose with magnet, whereas the survival rate increased from 19 to 34 days (p < 0.005) when the magnetic targeting strategy was applied (Figure 4b ). Results confirmed our hypothesis that improvement in cancer therapy in vivo can be achieved and lower drug doses can be given systemically without compromising the therapeutic efficacy when optimal magnetic targeting conditions are employed.
Tumors were also terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-stained to determine the degree of apoptosis after DTX therapy and histologically examined using hematoxylin and eosin (H&E) staining ( Figure  4c , right and left panels, respectively). Tumors from PBS, empty m-NCs, and free DTX groups exhibited few green patches (apoptotic cells), which were observed mainly at the tumor periphery. Expectedly, larger apoptotic areas were found in m-NC-DTX (L and H) treated tumors, more significantly with the ones subjected to magnetic field. H&E staining of fixed tissue sections showed no major signs of necrosis in the major organs of mice in all experimental groups except for DTX H , in which spleen angiectasis and hemorrhage associated with fibrosis were found ( Figure S16a) . These abnormalities were not seen at lower doses (5 mg/kg) or the same dose in m-NC formulation (m-NC-DTX H ). The inflammation-mediated toxicity (TNF-α levels) and liver function (liver biomarker level) were also assessed after the systemic administration of m-NCs or m-NC-DTX. No obvious increase was observed in both tests compared to the results from negative controls (Figures S16b and S17). Overall, these results suggest the biocompatibility of the formulated m-NCs in vivo under the conditions tested, and the m-NC formulation significantly reduced the systemic toxicity of DTX.
This study was designed to enable better understanding of the factors crucial for magnetic drug targeting in mice following intravenous administration and, furthermore, to extrapolate those preclinical findings to humans. Mathematical modeling was undertaken to compute the in vivo magnetic, viscoelastic, convective, and diffusive forces acting on m-NCs in accordance with the Nacev−Shapiro construct, and parameters were determined for which the theory successfully predicted the observed murine data. These parameters were then used to extrapolate to the expected behavior in humans, both generally and for the previously reported case conditions of a clinical trial on magnetic targeting to superficial solid tumors. The model predicted that in the latter case, the m-NCs and magnetic forces applied here would have been sufficient to achieve successful targeting in humans. Lastly, an in vivo murine tumor growth delay study was performed using the 2% w/w SPION−NC nanocapsules with docetaxel (DTX), an anticancer drug, incorporated into the oil core. Magnetic targeting was found to offer enhanced therapeutic efficacy and improved mice survival compared to the results from passive targeting at a drug dose of ca. 5−8 mg of DTX/kg. This work presented here bridges the gap between preclinical experiments and clinical translation in the field of magnetic drug targeting. Conceptual advance in both the fundamental scientific understanding of the technology and its performance have been made during this work. This is exampled by the ability to calculate the magnetic force exerted on each nanocapsule and links such values to the preclinical targeting data. Such values were used to extrapolate magnetic targeting efficiency from mouse to human. The method can be used to predict magnetic targeting efficiency in preclinical or clinical subjects once information on the diameters of SPION and the magnetic carrier, the tumor's position in relation to the magnet, and blood vessels characteristics become available. Conversely, the method allows us to design magnetic field setups of characteristics optimal for achieving the most-efficient magnetic targeting in vivo for a bespoken magnetic nanocarrier. 
